These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31952454)

  • 1. The economic impact of clinically significant tricuspid regurgitation in a large, administrative claims database.
    Cork DP; McCullough PA; Mehta HS; Barker CM; Van Houten J; Gunnarsson C; Ryan MP; Baker ER; Mollenkopf S; Verta P
    J Med Econ; 2020 May; 23(5):521-528. PubMed ID: 31952454
    [No Abstract]   [Full Text] [Related]  

  • 2. Healthcare utilization in clinically significant tricuspid regurgitation patients with and without heart failure.
    Barker CM; Cork DP; McCullough PA; Mehta HS; Houten JV; Gunnarsson C; Mollenkopf S; Verta P
    J Comp Eff Res; 2021 Jan; 10(1):29-37. PubMed ID: 33174767
    [No Abstract]   [Full Text] [Related]  

  • 3. The Economic Impact of Mitral Regurgitation on Patients With Medically Managed Heart Failure.
    McCullough PA; Mehta HS; Barker CM; Cork DP; Gunnarsson C; Ryan MP; Baker ER; Van Houten J; Mollenkopf S; Verta P
    Am J Cardiol; 2019 Oct; 124(8):1226-1231. PubMed ID: 31470974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Survival in Patients With Clinically Significant Tricuspid Regurgitation With and Without Heart Failure (From the Optum Integrated File).
    Barker CM; Cork DP; McCullough PA; Mehta HS; Van Houten J; Gunnarsson C; Ryan M; Irish W; Mollenkopf S; Verta P
    Am J Cardiol; 2021 Apr; 144():125-130. PubMed ID: 33385352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tricuspid regurgitation in acute heart failure: is there any incremental risk?
    Mutlak D; Lessick J; Khalil S; Yalonetsky S; Agmon Y; Aronson D
    Eur Heart J Cardiovasc Imaging; 2018 Sep; 19(9):993-1001. PubMed ID: 29346535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Tricuspid Regurgitation in Patients With Heart Failure and Mitral Valve Disease from a Nationwide Cohort Study.
    Kadri AN; Gajulapalli RD; Sammour YM; Chahine J; Nusairat L; Gad MM; Al-Khadra Y; Hernandez AV; Rader F; Harb SC; Kapadia S
    Am J Cardiol; 2019 Sep; 124(6):926-931. PubMed ID: 31331634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure.
    De la Espriella R; Santas E; Chorro FJ; Miñana G; Soler M; Bodí V; Valero E; Núñez E; Bayés-Genis A; Lupón J; Sanchis J; Núñez J
    Int J Cardiol; 2019 Sep; 291():83-88. PubMed ID: 30955879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting.
    Topilsky Y; Maltais S; Medina Inojosa J; Oguz D; Michelena H; Maalouf J; Mahoney DW; Enriquez-Sarano M
    JACC Cardiovasc Imaging; 2019 Mar; 12(3):433-442. PubMed ID: 30121261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tricuspid regurgitation in elderly patients with acute heart failure: insights from the KCHF registry.
    Obayashi Y; Kato T; Yaku H; Morimoto T; Seko Y; Inuzuka Y; Tamaki Y; Yamamoto E; Yoshikawa Y; Kitai T; Taniguchi R; Iguchi M; Kato M; Takahashi M; Jinnai T; Ikeda T; Nagao K; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Su K; Kawato M; Inoko M; Toyofuku M; Furukawa Y; Nakagawa Y; Ando K; Kadota K; Shizuta S; Ono K; Sato Y; Kuwahara K; Ozasa N; Kimura T;
    ESC Heart Fail; 2023 Jun; 10(3):1948-1960. PubMed ID: 36992608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.
    Rice JB; White AG; Johnson M; Wagh A; Qin Y; Bartels-Peculis L; Ciepielewska G; Nelson WW
    J Med Econ; 2018 Sep; 21(9):846-852. PubMed ID: 29741439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and impact of preoperative moderate/severe tricuspid regurgitation on patients undergoing transcatheter aortic valve replacement.
    Barbanti M; Binder RK; Dvir D; Tan J; Freeman M; Thompson CR; Cheung A; Wood DA; Leipsic J; Webb JG
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):677-84. PubMed ID: 24740834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
    Watson C; Xu H; Princic N; Sruti I; Barlev A
    J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis.
    Messika-Zeitoun D; Verta P; Gregson J; Pocock SJ; Boero I; Feldman TE; Abraham WT; Lindenfeld J; Bax J; Leon M; Enriquez-Sarano M
    Eur J Heart Fail; 2020 Oct; 22(10):1803-1813. PubMed ID: 32367642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts.
    Obi EN; Swindle JP; Turner SJ; Russo PA; Altan A
    Adv Ther; 2017 Jan; 34(1):261-276. PubMed ID: 27933568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world annualized healthcare utilization and expenditures among insured US patients with acute intermittent porphyria (AIP) treated with hemin.
    Blaylock B; Epstein J; Stickler P
    J Med Econ; 2020 Jun; 23(6):537-545. PubMed ID: 31999204
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of concomitant tricuspid regurgitation on long-term outcomes in severe aortic stenosis.
    Amano M; Izumi C; Taniguchi T; Morimoto T; Miyake M; Nishimura S; Kitai T; Kato T; Kadota K; Ando K; Furukawa Y; Inada T; Inoko M; Ishii K; Sakaguchi G; Yamazaki F; Koyama T; Komiya T; Yamanaka K; Nishiwaki N; Kanemitsu N; Saga T; Ogawa T; Nakayama S; Tsuneyoshi H; Iwakura A; Shiraga K; Hanyu M; Ohno N; Fukumoto A; Yamada T; Nishizawa J; Esaki J; Minatoya K; Nakagawa Y; Kimura T
    Eur Heart J Cardiovasc Imaging; 2019 Mar; 20(3):353-360. PubMed ID: 30085068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The healthcare burden of disease progression in medicare patients with functional mitral regurgitation.
    McCullough PA; Mehta HS; Cork DP; Barker CM; Gunnarsson C; Mollenkopf S; Van Houten J; Verta P
    J Med Econ; 2019 Sep; 22(9):909-916. PubMed ID: 31104524
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of Tricuspid Regurgitation on the Reported Quality of Life and Subsequent Outcomes in Patients With Atrial Fibrillation.
    Fujisawa T; Kimura T; Ikemura N; Miyama H; Katsumata Y; Ueda I; Tanimoto K; Kanki H; Fukuda K; Kohsaka S; Takatsuki S
    J Am Heart Assoc; 2022 Apr; 11(8):e022713. PubMed ID: 35383465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension.
    Chen L; Larsen CM; Le RJ; Connolly HM; Pislaru SV; Murphy JG; McGoon MD; Frantz RP; Kane GC
    Clin Respir J; 2018 Apr; 12(4):1572-1580. PubMed ID: 28905517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.
    Trantham L; Sikirica MV; Candrilli SD; Benson VS; Mohan D; Neil D; Joshi AV
    J Med Econ; 2019 Apr; 22(4):319-327. PubMed ID: 30580639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.